IN8bio, Inc. announced a presentation demonstrating that INB-300, its preclinical DeltEx drug resistant immunotherapy platform, or DRI, CAR-T candidate has enhanced persistence and cytotoxicity against glioblastoma multiforme (GBM) cells. The poster (abstract #1490), entitled “Dual chlorotoxin and methylguanine methyltransferase ?d-T cells for drug resistant immunotherapy of Glioblastoma Multiforme,” will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 on April 10 by Lei Ding, Ph.D., the program’s lead scientist at IN8bio. The in vitro work presented at AACR demonstrates that the DeltEx DRI CAR-T modified cells can bind GBM cell lines and induce cellular activation as well as demonstrate significant cytotoxic killing and persistence. The DeltEx platform encompasses IN8bio’s ex vivo expansion, genetic engineering and scalable manufacturing capabilities with gamma-delta T cells. This platform harnesses the unique properties of gamma-delta T cells for solid tumor cancer therapies. INB-300 is DeltEx DRI Chlorotoxin CAR-T preclinical candidate that combines expertise in gamma-delta T cells, DeltEx DRI technology and a novel Chlorotoxin targeting CAR. Chlorotoxin is a small peptide derived from scorpion venom, which binds to multiple solid tumor cancers including lung, ovarian, breast and prostate among others. This dual-chlorotoxin CAR-T construct is designed to confer both TMZ resistance, enhance the tumor-targeting/trafficking capabilities, and increase persistence of the gamma-delta T cells. This program is currently advancing into animal models and provides a unique approach to targeting solid tumor cancers.